



HAL
open science

Unusual arterial thrombotic events in Covid-19 patients

C. de Roquetaillade, B.G. Chousterman, D. Tomasoni, M. Zeitouni, E. Houdart, A. Guedon, P. Reiner, R. Bordier, E. Gayat, G. Montalescot, et al.

► **To cite this version:**

C. de Roquetaillade, B.G. Chousterman, D. Tomasoni, M. Zeitouni, E. Houdart, et al.. Unusual arterial thrombotic events in Covid-19 patients. *International Journal of Cardiology*, 2021, 323, pp.281 - 284. 10.1016/j.ijcard.2020.08.103 . hal-03492606

HAL Id: hal-03492606

<https://hal.science/hal-03492606>

Submitted on 15 Dec 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Title: Unusual arterial thrombotic events in Covid-19 patients

Authors : C. de Roquetaillade (1, 2), BG. Chousterman (1, 2, 3), D. Tomasoni (4), M. Zeitouni (5), E. Houdart (6), A. Guedon (6), P. Reiner (7), R. Bordier (1), E. Gayat (1, 2, 3), G. Montalescot (5), M. Metra (4), A. Mebazaa (1, 2, 3)

(1) Department of Anesthesiology and Critical Care, Hôpital Lariboisière (AP-HP), Paris, France.

(2) Inserm U942 MASCOT, Paris, France

(3) Université de Paris, Paris, France.

(4) Cardiothoracic Department, Civil Hospitals and University of Brescia, Brescia, Italy.

(5) Sorbonne Université, Action Study Group, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France.

(6) Departments of Interventional Neuroradiology, Hôpital Lariboisière (AP-HP), Paris, France

(7) Department of Neurology, Hôpital Lariboisière (AP-HP), Paris, France.

Corresponding author :

Charles de Roquetaillade,

Inserm U942 MASCOT,

Université de Paris, Hôpital Lariboisière - Bâtiment Viggo Petersen ;

41, boulevard de la Chapelle 75475 Paris Cedex 10

Téléphone : +33 (0)1 53 21 67 60 ;

Mail : charles.de-roquetaillade@aphp.fr

KEYWORDS : SARS-CoV-2, Covid-19, arterial thrombosis, anticoagulation, acute coronary syndrom

INTRODUCTION:

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is commonly complicated with pro-thrombotic state and endothelial dysfunction¹. Excess of venous thromboembolic events (deep vein thrombosis (DVT), pulmonary embolism (PE)) have been described among patients suffering from coronavirus disease 2019 (Covid-19)². However, arterial thrombosis are yet rarely described in this setting and could be underestimated³. Here we report our multicentric experience with patients suffering from arterial thromboembolic events during the first months of the Covid-19 outbreak in Western Europe.

MATERIAL AND METHOD:

During a six weeks period (March 8th to April 25th 2020) we performed a retrospective study in three critical care departments. Patients with a confirmed SARS-CoV-2 infection (rt-PCR) and arterial thromboembolic events were included in the analysis. Baseline characteristics, biological findings and imaging were extracted from medical records. For most patients, antithrombotic prophylaxis was made of 4000 ui per day of enoxaparine administered subcutaneously, the dose was increased (6000UI/day or 8000UI/day) in case of obesity (BMI > 30 kg/m²). In patient treated with therapeutic dose anticoagulant, the therapeutic objectives followed international recommendations (AntiXa activity 0.3-0.6 for unfractionated heparin (UFH), and no systematic AntiXa monitoring for low-molecular-weight heparin (LMWH) treatment except for patient at risk of altered renal function or obese or unstable patients, for those the AntiXa was monitored and the LMWH doses were adapted for an AntiXa activity between 0.5-1.2 UI/mL). For the descriptive analysis, continuous variables were expressed as median (interquartile range) and categorical variables as numbers (percentages). This study was approved by our local committee (Institutional Review Board -IRB 00006477- of HUPNVS, Paris 7 University, AP-HP).

RESULTS:

We report a total of 20 patients out of a total of 209 patients (9.6%) observed of COVID-19 patients suffering from arterial thromboses. Among them 4 patients had multiple arterial thrombotic events, accounting for a total of 24 events (**Table**). A total of 5/20 (25%) patients had ischemia-related symptoms (sudden neurologic deficit or acute coronary syndrome) at the time of presentation and the other 15/20 patients developed ischemia during hospitalization. Reported arterial thrombotic events were acute coronary occlusions (n=9), stroke (n=6), limb ischemia (n=3), splenic infarcts (n=3), aortic thrombosis (n=2) and occlusive mesenteric ischemia (n=1). Four patients developed multiple arterial event during their stay. Those patient had no concomitant venous thromboembolism nor patent foramen ovale (PFO). Only two patients (one patient with stroke and one patient with splenic infarct) had associated PFO but no concomitant deep vein thrombosis nor pulmonary embolism. The majority (15/20) of patients were male, with a median age of 62 (interquartile range 58-70) years. The time from onset of symptoms to arterial thrombotic events was 11 (7-13) days. A total of 10/20 patients were receiving antithrombotic prophylaxis at the time of event (enoxaparine 4000UI/24h (n=6), 8000UI/24h (n=3), 6000UI/24h (n=1) and 2/20 patients were receiving treatment dose anticoagulation (one with UFH 20000ui/day and one with LMWH 6000UIx2/24h). 4/20 patients (20%) received aspirin and 2/20 (10%) were receiving PY214 inhibitor. Regarding therapeutic intervention, thrombolysis was attempted in one patient with stroke (failure), primary Percutaneous Coronary Intervention was successfully attempted in 3 patients with ST-segment elevation myocardial infarction, and thrombectomy was performed in 3 patients with stroke (1 failure, 2 successes). One patient underwent successful thrombectomy for acute limb ischemia, however, he presented a fatal relapse few days later. Surprisingly, no patient was actively smoking at the time of the event.

At the time of event, the average levels of fibrinogen and D-Dimer were 7.1 (5.0-7.4) g/L and 2725 (848-4163) ng/mL, respectively. Six patients (30%) had a concomitant venous thromboembolic event (pulmonary embolism or lower limb DVT). All patients, except one, who was receiving curative anticoagulant, were in sinus rhythm. No patient had thrombocytopenia at the time of the event and median platelet count was of 294 (212-386) $\times 10^3/\text{mm}^3$. anti-PF4 antibody research conducted in 3 patients was negative. ADAMTS13 activity tested in 2 patients was normal. A total of 4 patients (20%) died in the hospital, all from complications due to ischemia (extended aortic thrombosis (n=1) (**Figure**), mesenteric ischemia (n=1), fatal cardiogenic shock (n=1) and devastating brain injury (n=1)).

DISCUSSION:

In this multicentric serie of patients, severe SARS-CoV-2 infection was complicated with atypical severe arterial thrombotic events including acute coronary infarction, stroke, and limb ischemia not prevented by thromboprophylaxis. Thromboses we observed occurred mainly on non-atherosclerotic vessels. Patients were of relatively young age and available CT-scans and angiography revealed no prior major atherosclerosis. Our observations suggest that a significative proportion of arterial thromboses in Covid-19 patients might occur over non diseased or mildly diseased vessels⁴. A prothrombotic state might be triggered by various mechanisms such as inflammation, endothelial injury or vascular injury⁵. Taken together, our observations suggest that serious arterial thrombotic events occur in Covid-19 patients who exhibit high inflammation and sometimes unusual localisation of these thrombotic events. Those arterial thromboses might be reason for admission but can also occur during hospitalisation of patients with Covid-19. Several recommandations were emitted by several groups regarding VTE prevention and management⁶ same as ACS occuring among Covid-19

patients ⁷. However, the best prevention and management of arterial thromboses in the Covid-19 context remains to be elucidated.

REFERENCES:

1. Thachil J. The versatile heparin in COVID-19. *J Thromb Haemost*. Epub ahead of print 2 April 2020. DOI: 10.1111/jth.14821.
2. Llitjos J-F, Leclerc M, Chochois C, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. *Journal of Thrombosis and Haemostasis*; n/a. DOI: 10.1111/jth.14869.
3. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb Res*. Epub ahead of print 10 April 2020. DOI: 10.1016/j.thromres.2020.04.013.
4. Stefanini GG, Montorfano M, Trabattoni D, et al. ST-Elevation Myocardial Infarction in Patients with COVID-19: Clinical and Angiographic Outcomes. *Circulation*. Epub ahead of print 30 April 2020. DOI: 10.1161/CIRCULATIONAHA.120.047525.
5. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. *The Lancet*; 0. Epub ahead of print 20 April 2020. DOI: 10.1016/S0140-6736(20)30937-5.
6. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. *Journal of Thrombosis and Haemostasis*; n/a. DOI: 10.1111/jth.14810.
7. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. *Journal of the American College of Cardiology* 2020; 75: 2950–2973.

Conflict of interest : all authors declare no conflict of interest in relation with the present study

Role and contribution of the authors: CdR designed the study, collected data and wrote the manuscript. DT, MZ, AG, PR, RB, TM collected data, images and wrote the manuscript. BGC, EH, EG, MM, GM and AM designed the study and wrote the manuscript.

Figure Legend. Fatal aortic thrombosis in COVID-19 patient.

Arterial-TDM showing extended intra-luminal aortic thrombi in a patient suffering from COVID-19.

A 74 years old patient was admitted in ICU for respiratory failure. Nasal swab confirmed the suspected COVID-19. Doppler ultrasound revealed no deep venous thrombosis despite D-dimers >20 000UI/L. The patient received prophylactic enoxaparin (4000UI/12h). On the 6th day, the patient presented lower limb ischemia and abdominal occlusion syndrome. Subsequent Arterial-TDM revealed *de novo* multifocal and circumferential aortic thrombi of suprarenal and subrenal localization, with up to 50% occlusion on the infra-renal portion. There were no associated deep vein thrombosis nor pulmonary embolism.



Table . Characteristics of 20 patients with Covid-19 with arterial thrombotic event

Characteristics	All n=20 / number available	ACS n=9	Stroke n=6	Other ¹ n= 5
Median age, year (interquartile range)	62 (58-70)	60 (57-71)	59 (52-67)	65 (62-71)
Male sex, n (%)	15 (75)	6 (67)	4 (67)	5 (100)
Ethnicity				
Caucasian, n (%)	13 (65)	7 (78)	4 (67)	2 (40)
Sub-Saharan African, n (%)	7 (35)	2 (22)	2 (33)	3 (60)
Cardiovascular Risk factors				
Hypertension, n (%)	14 (70)	6 (67)	3 (50)	5 (100)
Dyslipidemia, n (%)	5 (25)	3 (33)	2 (33)	0 (0)
Diabetes mellitus, n (%)	4 (20)	1 (11)	2 (33)	1 (20)
Obesity, n (%)	3 (15)	0 (0)	2 (33)	1 (20)
Peripheral artery disease, n (%)	2 (10)	0 (0)	1 (17)	1 (20)
COPD, n (%)	1 (5)	0 (0)	0 (0)	1 (20)
Previous DVT or PE, n (%)	1 (5)	1 (11)	0 (0)	0 (0)
Myocardial infarction, n (%)	4 (20)	3 (33)	1 (17)	0 (0)
Prior stroke, n (%)	1 (5)	1 (11)	0 (0)	0 (0)
≥ 2 risk factors	9 (45)	4 (44)	3 (50)	2 (40)
Chronic medication				
ACEi/ARB, n (%)	8 (40)	3 (33)	1 (17)	4 (80)
Aspirin, n (%)	4 (20)	3 (33)	0 (0)	1 (20)
P2Y12 inhibitor, n (%)	2 (10)	1 (11)	1 (17)	0 (0)
Anticoagulant, n (%)	1 (5)	1 (11)	0 (0)	0 (0)
Motif of admission				
Shortness of breath, n (%)	9 (45)	3 (33)	3 (50)	3 (60)
Fever, cough, n (%)	5 (25)	1 (11)	2 (33)	2 (40)
Ischemia related symptom, n (%)	5 (25)	4 (44)	1 (17)	0 (0)
Characteristic on admission				
SAPS II	33 (23-66)	36 (30-63)	23 (18-68)	27 (25-65)
SOFA	2 (2-9)	2 (1-4)	3 (2-12)	3 (2-11)
Charlson comorbidity score	2 (1-3)	1 (1-1)	1 (1-3)	1 (1-4)
Patient under mechanical ventilation, n (%)	5 (25)	1 (11)	2 (33)	2 (40)
P/F ratio	200 (128-294) /15	308 (222-342)/4	188 (156-260)	168 (106-233)
Median Laboratory values at time of event (median, interquartile range, n)				
White cell count, x10 ³ /mm ³	11.9 (8.1-14.0) /20	12.3 (5.4-13.2)	10.3 (7.5-12.3)	12.9 (11.4-16.9)
Neutrophils, x10 ³ /mm ³	10.2 (8.7-10.7) /17	9.5 (4-11.7)	8.9 (8.6-9.4)	12.1 (10.5-14.8)
Lymphocytes, x10 ³ /mm ³	1.03 (0.84-1.5) /18	1.1 (0.9-1.3)	0.9 (0.9-1.5)	0.9 (0.5-1.3)

Platelet, x10 ³ /mm ³	294 (212-386) /19	262 (216-295)	382 (153-421)	324 (220-389)
Ferritin, µg/L	1162 (509-1857) /10	689 (537-951) /3	1270 (978-2231)/4	2000 (1225-2891) / 3
CRP, mg/L	92 (22-146) / 16	26 (16-146)	105v(73-127)/4	114 (69-277)/3
D-Dimer, ng/ml	2725 (848-4163)/20	890 (651-1429)	4700 (2867-7417)	3900 (3380-4204)
Fibrinogen, g/L	7.1 (5.0-7.4)/19	4.9 (3.6-6.7)	7.1 (6.6-7.1)	7.8 (5.8-8.8)/4
INR	1.12 (1.04-1.21) / 20	1.1 (1.0-1.2)	1.1 (1.1-1.2)	1.4 (1.3-1.9)
aPTT	1.06 (0.91-1.1) / 14	1.05 (1.03-1.09) /7	0.9 (0.8-1.0) / 4	1.1 (0.9-4.3) / 3
vW Factor activity, %	>200 (200-200) / 3	-	-	>200 (200-200) / 3
ADAMTS13 activity, %	68 (66-70) / 2	-	-	68 (66-70) / 2
AT III activity, %	108 (99-114) / 4	-	-	113 (100-115)/ 3
FV Leiden or factor II mutation, n (%)	0 (0) /3	-	-	0 (0) /3
Lupic anticoagulant, n (%)	0 (0) /5	-	-	0 (0) /5
Anti-PF4 antibody, n (%)	0 (0) /3	-	-	0 (0) /3
Patent foramen ovale, n (%)	2 (10) /12	0 (0) / 3	1 (17) / 5	1 (20) / 4
Treatment				
Antiplatelet therapy at time of event, n (%)	4 (20)	3 (33)	0 (0)	1 (20)
Anticoagulant at time of event, n (%)	12 (60)	7 (63)	2 (33)	3 (60)
Antibiotic, n (%)	14 (70)	6 (67)	5 (83)	3 (60)
Glucocorticoids, n (%)	4 (20)	1 (11)	2 (33)	1 (20)
Hydroxychloroquine, n (%)	11 (55)	4 (44)	4 (67)	3 (60)
Tocilizumab or other anti IL6, n (%)	1 (5)	0 (0)	1 (17)	0 (0)
Characteristic of thrombotic event				
Time from symptom onset, days	11 (7-13)	8 (4-10)	9 (7-12)	14 (13-25)
Time from hospital admission, days	0.5 (0-5)	0 (0-0)	3 (0-5)	7 (5-11)
Multiple arterial ischemic event	4 (20)	2 (22)**	2 (33)*	0 (0)
Associated PE or phlebitis, n (%)	6 (30)	1 (11)	2 (33)	3 (60)
Outcome				
pPCI	3 (15)	3 (33)	0 (0)	0 (0)
Thrombectomy, n (%)	4 (20)	0 (0)	3 (50)	1 (20)
Thrombolysis, n (%)	1 (5)	0 (0)	1 (17)	0 (0)
Mechanical ventilation, n (%)	9 (45)	3 (33)	2 (33)	3 (60)
AKI, n (%)	10 (50)	2 (22)	1 (17)	4 (80)
Hospital Mortality, n (%)	4 (20)	2 (22)	1 (17)	1 (20)

[†] aortic thrombosis, (n=2), acute limb ischemia (n=2), splenic infarct (n=1)

*One patient had concomitant limb ischemia, another patient had concomitant splenic infarct. No patent foramen ovale was retrieved among these patients

**** One patient had concomitant splenic infarct, another patient had concomitant mesenteric ischemia. No concomitant venous thromboembolism nor patent foramen ovale**

ACS: Acute coronary syndrome ; COPD : Chronic Obstructive Pulmonary Disease ; DVT : Deep Vein Thrombosis ; PE : Pulmonary embolism ; ACEi : angiotensine converting enzyme inhibitor ; ARB : angiotensin receptor blocker ; SAPS : Simplified Acute Physiology Score; SOFA : Sequential Organ Failure Assessment ; LMWH : Low Molecular Weight Heparin ; UFH : Unfractionated Heparin ; NOACS : New Oral Anticoagulant ; **PCI: Percutaneous coronary intervention;** AKI : Acute Kidney Injury

